HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The Role of Intravitreal Anti-VEGF Agents in Rabbit Eye Model of Open-Globe Injury.

AbstractPURPOSE:
To evaluate the effects of intravitreal anti-VEGF agents in a rabbit model of open-globe injury (OGI).
METHODS:
OGI was induced in the right eyes of 75 Belgian rabbits by making 5 mm circumferential incision placed 6 mm behind the limbus. The rabbits were divided into 4 groups: control (n = 5), OGI group (n = 40), and intravitreal Ranibizumab and Conbercept (n = 15 each). Ranibizumab or Conbercept was injected into the vitreous at 0.5 hours, 3 days, or 7 days. Vitreous fluid was collected, and levels of growth factors and cytokines were measured by enzyme-linked immunosorbent assay (ELISA). On day 28 after OGI, B scan examination and histological examination were performed to evaluate intravitreal proliferation and formation of epiretinal fibrosis.
RESULTS:
Vitreous levels of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and plasminogen activator inhibitor-1 (PAI-1) were significantly increased in rabbit eyes after OGI. Compared to eyes in OGI group, anti-VEGF treatments significantly reduced these growth factors and cytokines. Among the 7 eyes examined from each group for intravitreal proliferative changes, they were found in 7 of 7 (100%) in OGI group and were decreased by Ranibizumab and Conbercept to 5 of 7 (71.4%) and 4 of 7 (57.1%), respectively. Both Ranibizumab and Conbercept inhibited epiretinal scar formation at the wound site, with Conbercept showing the greatest effect (maximal length of scar (L), L OGI = 503 ± 82.44 μm, L Ranibizumab = 355 ± 43.66 μm, and L Conbercept = 250.33 ± 36.02 μm).
CONCLUSION:
Anti-VEGF treatments after OGI significantly attenuated the upregulation of growth factors and cytokines in the vitreous and prevented intravitreal proliferation and epiretinal scar formation and thus may protect against the development of posttraumatic complications such as proliferative vitreoretinopathy (PVR).
AuthorsXiao Zhao, Han Han, Yinting Song, Mei Du, Mengyu Liao, Xue Dong, Xiaohong Wang, Ferenc Kuhn, Annette Hoskin, Heping Xu, Hua Yan
JournalJournal of ophthalmology (J Ophthalmol) Vol. 2021 Pg. 5565178 ( 2021) ISSN: 2090-004X [Print] United States
PMID33953964 (Publication Type: Journal Article)
CopyrightCopyright © 2021 Xiao Zhao et al.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: